Rotating and positive-displacement pumps for low-thrust rocket engines. Volume 1: Pump Evaluation and design

Rotating and positive displacement pumps of various types were studied for pumping liquid fluorine for low-thrust, high-performance rocket engines. Included in the analysis were: centrifugal, pitot, Barske, Tesla, drag, gear, vane, axial piston, radial piston, diaphragm, and helirotor pump concepts. The centrifugal pump and the gear pump were selected and these were carried through detailed design and fabrication. Mechanical difficulties were encountered with the gear pump during the preliminary tests in Freon-12. Further testing and development was therefore limited to the centrifugal pump. Tests on the centrifugal pump were conducted in Freon-12 to determine the hydrodynamic performance and in liquid fluorine to demonstrate chemical compatibility

Advanced Launch System propulsion focused technology liquid methane turbopump technical implementation plan

This program will focus on the integration of all functional disciplines of the design, manufacturing, materials, fabrication and producibility to define and demonstrate a highly reliable, easily maintained, low cost liquid methane turbopump as a component for the STBE (Space Transportation Booster Engine) using the STME (main engine) oxygen turbopump. A cost model is to be developed to predict the recurring cost of production hardware and operations. A prime objective of the program is to design the liquid methane turbopump to be used in common with a LH2 turbopump optimized for the STME. Time phasing of the effort is presented and interrelationship of the tasks is defined. Major subcontractors are identified and their roles in the program are described

Turbopumps for cryogenic upper stage engines

Small, high-performance LO2 and LH2 turbopump assembly configurations were selected, detail designs were prepared and two of each unit were fabricated with each unit consisting of pump, turbine gas generator, and appropriate controls. Following fabrication, development testing was conducted on each type to demonstrate performance, durability, transient characteristics, and heat transfer under simulated altitude conditions. Following successful completion of development effort, the two LO2 turbopump units and one LH2 turbopump unit were acceptance tested as specified. Inspection of the units following development testing revealed no deleterious effects of testing. The test results of LO2 turbopump assembly testing correlated well with predicted performance while the LH2 turbopump test results, though generally consistent with predicted values, did show lower than anticipated developed head at the design point and in the high flow range of operation

Rotating and positive-displacement pumps for low-thrust rocket engines. Volume 2: Fabrication and testing

Rotating and positive displacement pumps of various types were studied for pumping liquid fluorine for low thrust high performance rocket engines. Included in the analysis were: centrifugal, pitot, Barske, Tesla, drag, gear, vane, axial piston, radial piston, diaphragm and helirotor pump concepts. The centrifugal and gear pumps were carried through detail design and fabrication. After preliminary testing in Freon 12, the centrifugal pump was selected for further testing and development. It was tested in Freon 12 to obtain the hydrodynamic performance. Tests were also conducted in liquid fluorine to demonstrate chemical compatibility

Small, high-pressure, liquid oxygen turbopump

A small, high-pressure, LOX turbopump was designed, fabricated, and tested. The pump was of a single-stage, centrifugal type; power to the pump was supplied by a single-stage, partial-admission, axial-impulse turbine. Design conditions included an operating speed of 7330 rad/sec (70,000 rpm) pump discharge pressure of 2977 N/sq cm (4318 psia), and a pump flowrate of 16.4 kg/s (36.21 lb/sec). The turbine was propelled by LOX/LH2 combustion products at 1041 K (1874 R) inlet temperature, and at a design pressure ratio of 1.424. Test data obtained with the turbopump are presented and mechanical performance is discussed

Small, high-pressure liquid oxygen turbopump

A small, high-pressure, liquid oxygen turbopump was designed, fabricated, and tested. The pump was of a single-stage, centrifugal type; power to the pump was supplied by a single-stage, partial emission, axial-impulse turbine. Design conditions included an operating speed of 70,000 rpm, pump discharge pressure of 2977 N/sq cm (4318 psia), and a pump flowrate of 16.4 kg/s (36.21 lb/sec). The turbine was propelled by LO2/LH2 combustion products at 1041 K (1874 R) inlet temperature, and at a design pressure ratio of 1.424. The approaches used in the detail analysis and design of the turbopump are described, and fabrication methods are discussed. Data obtained from gas generator tests, turbine performance calibration, and turbopump testing are presented

Small, high-pressure liquid hydrogen turbopump

A high pressure, liquid hydrogen turbopump was designed, fabricated, and tested to a maximum speed of 9739 rad/s and a maximum pump discharge pressure of 2861 N/sq. cm. The approaches used in the analysis and design of the turbopump are described, and fabrication methods are discussed. Data obtained from gas generator tests, turbine performance calibration, and turbopump testing are presented

Sarcoidosis lymphoma syndrome - the value of PET-CT in the diagnosis

We report a 52-year-old patient who developed B-cell non-Hodgkin's lymphoma subsequent to sarcoidosis. Sarcoidosis was diagnosed 16 years ago and remained asymptomatic for 14 years after steroid treatment. She presented with new symptoms of arthralgia, photosensitivity, butterfly erythema, autoimmune antibodies (ANA, chromatin positivity) associated with progression of the known left upper lobe lesion on the chest X-ray suggesting primary autoimmune disease (systemic lupus erythematosus). As steroid treatment was not effective, we started bolus cyclophosphamide therapy after which progression was seen on the chest X-ray. Computed tomography (CT)-guided needle biopsy confirmed malignancy of indefinable origin. Despite of the well-known fluorodeoxyglucose (FDG) avidity in active sarcoidosis, a FDG-positron emission tomography (PET) scan was performed to stage the primary tumour. Intensive FDG uptake was detected in the affected lung segment, with moderate uptake in mediastinal lymph nodes. The patient underwent left upper lobectomy. The histology showed pulmonary mucosa-associated lymphoma (bronchus-associated lymphoid tissue (BALT) lymphoma) in the lung tissue, while only sarcoidosis was present in the mediastinal lymph nodes. Bone marrow biopsy was negative.The association between sarcoidosis and lymphoma is known as sarcoidosis lymphoma syndrome, which is a rare disease. PET-CT was helpful in the differentiation of sarcoidosis and malignancy in this patient. It is important to be aware of the risk of lymphoma in sarcoidosis and FDG-PET, used for adequate purpose, can help the diagnosis

Komplex molekuláris genetikai vizsgálati algoritmus myeloproliferativ neoplasiák diagnosztikájában

Introduction: Mutations in Janus kinase 2, calreticulin and thrombopoietin receptor genes have been identified in the genetic background of Philadelphia chromosome negative, "classic" myeloproliferative neoplasms. Aim: The aim of the authors was to identify driver mutations in a large myeloproliferative cohort of 949 patients. Method: A complex array of molecular techniques (qualitative and quantitative allele-specific polymerase chain reactions, fragment analyzes, high resolution melting and Sanger sequencing) was applied. Results: All 354 patients with polycythemia vera carried Janus kinase 2 mutations (V617F 98.6%, exon 12: 1.4%). In essential thrombocythemia (n = 468), the frequency of V617F was 61.3% (n = 287), that of calreticulin 25.2% (n = 118), and that of thrombopoietin receptor mutations 2.1% (n = 10), while 11.3% (n = 53) were triple-negative. Similar distribution was observed in primary myelofibrosis (n = 127): 58.3% (n = 74) V617F, 23.6% (n = 30) calreticulin, 6.3% (n = 8) thrombopoietin receptor mutation positive and 11.8% (n = 15) triple-negative. Conclusions: The recent discovery of calreticulin gene mutations led to definite molecular diagnostics in around 90% of clonal myeloproliferative cases. Orv. Hetil., 2014, 155(52), 2074-2081

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing, high resolution melting and Sanger-sequencing was applied for the detection of three driver mutations (in Janus kinase 2, calreticulin and myeloproliferative leukemia virus oncogene genes) in 289 cases of essential thrombocythemia and 99 cases of primary myelofibrosis. In essential thrombocythemia, 154 (53%) Janus kinase 2 V617F, 96 (33%) calreticulin, 9 (3%) myeloproliferative leukemia virus oncogene gene mutation-positive and 30 triple-negative (11%) cases were identified, while in primary myelofibrosis 56 (57%) Janus kinase 2 V617F, 25 (25%) calreticulin, 7 (7%) myeloproliferative leukemia virus oncogene gene mutation-positive and 11 (11%) triple-negative cases were identified. Patients positive for the calreticulin mutation were younger and had higher platelet counts compared to Janus kinase 2 mutation-positive counterparts. Calreticulin mutation-positive patients with essential thrombocythemia showed a lower risk of developing venous thrombosis, but no difference in overall survival. Calreticulin mutation-positive patients with primary myelofibrosis had a better overall survival compared to that of the Janus kinase 2 mutation-positive (P=0.04) or triple-negative cases (P=0.01). Type 2 calreticulin mutation occurred more frequently in essential thrombocythemia than in primary myelofibrosis (P=0.049). In essential thrombocythemia, the calreticulin mutational load was higher than the Janus kinase 2 mutational load (P<0.001), and increased gradually in advanced stages. Calreticulin mutational load influenced blood counts even at the time point of diagnosis in essential thrombocythemia. We confirm that calreticulin mutation is associated with distinct clinical characteristics and explored relationships between mutation type, load and clinical outcome